Muhammad Umair Mushtaq MD

Hematologic Oncology

Associate Professor, Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center

3901 Rainbow BlvdKansas City, KS 66160
Phone+1 913-945-5793

Dr. Mushtaq is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mushtaq's full profile Already have an account?

Summary

Dr. Muhammad Umair Mushtaq is an associate professor at the University of Kansas School of Medicine specializing in oncology, with a subspecialty in hematologic oncology. His education includes an MBBS from Allama Iqbal Medical College, a residency in internal medicine at Cook County Health, and a fellowship in hematology and medical oncology at University of Wisconsin Hospitals and Clinics. Dr. Mushtaq's experience spans bone marrow failure syndromes, transplantation, acute myeloid leukemia, multiple myeloma, and general hematology. He has authored several peer-reviewed publications in notable journals. He serves as principal investigator in clinical trials on treatments for melanoma and acute myeloid leukemia (AML). Recognitions include the Karl and Irene Eisemann Award and Clinical Research Excellence Award from the University of Kansas Medical Center, as well as the Robert Korngold Award from the American Society for Transplantation and Cellular Therapy.

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 2017 - 2020
Cook County Health and Hospitals SystemResidency, Internal Medicine, 2014 - 2017
Allama Iqbal Medical CollegeClass of 2010, MBBS

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

KS State Medical License 2020 - 2027
MO State Medical License 2021 - 2027
WI State Medical License 2017 - 2023
IL State Medical License 2014 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Karl and Irene Eisemann Award for Hematologic Malignancies and Cellular Therapeutics University of Kansas Medical Center, 2023
Clinical Research Excellence Award University of Kansas Medical Center, 2023
Robert Korngold Award for the Best Clinical Science in Cellular Therapy article American Society for Transplantation and Cellular Therapy, 2021

Clinical Trials

Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant Start of enrollment: 2023 Dec 11
TERMINATED
PHASE1, PHASE2
Roles: Contact, Principal Investigator
A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD) Start of enrollment: 2023 Apr 06
COMPLETED
PHASE1
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide Start of enrollment: 2020 Jan 31
RECRUITING
PHASE1

Publications & Presentations

PubMed

Outcomes after Matched Sibling Donor versus Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis.
Muhammad Umair Mushtaq, Amir Kasaeian, Tahereh Rostami, Muhammad Kashif Amin, Shayan Forghani
Transplantation and Cellular Therapy. 2026-08-18
From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myeloma.
Carmel Awadallah, Shebli Atrash, Barry Paul, Abdullah Mohammad Khan, Hira Shaikh
Expert Review of Hematology. 2026-08-01
Long-Term Gynecologic and Reproductive Health in Female Survivors of Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis of Preva...
Muhammad Kashif Amin, Nabeeha Noor, Muhammad Talha Maqsood, Hameer Ali, Hateem Ahmad
Transplantation and Cellular Therapy. 2026-08-01

Abstracts/Posters

The TACTUM23 Study: Access to Cellular Therapies in Multiple Myeloma: Perspectives of Treating Versus Referring Physicians in 2023
Atallah R, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S375-S376, 2/2024
The GLAMM1 Study - Global Access to Myeloma Medications: Potential Barriers to Chimeric Antigen Receptors (CART) and T-Cell-Engaging Bispecific Antibodies (TCE) Globally
Atallah R, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S373-S374, 2/2024
The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma
Khaliq A, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S208, 2/2024

Lectures

Highlights of American Society of Hematology Annual Meeting 2023. University of Kansas Cancer Center ASH Review
Kansas City, KS - 1/2024
Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients. Grand Rounds Speaker at the University of Kansas Me...
Kansas City, KS - 4/2022
Graft failure and graft rejection. American Society of Transplantation & Cellular Therapy Fall Clinical Education Conference (ASTCT CEC)
Virtual - 9/2021

Research History

Principal InvestigatorUniversity of Kansas Cancer Center, Kansas City, KS2020 - Present
Co-InvestigatorUniversity of Wisconsin Carbone Cancer Center, Madison, WI2017 - 2020
Co-InvestigatorCook County Health & Hospitals System, Chicago, IL2014 - 2017
Post-Doc Research AssociateColumbia University Irving Medical Center, New York, NY2013 - 2014
Principal InvestigatorPunjab Department of Health/Allama Iqbal Medical College, Lahore, Pakistan2008 - 2012

Professional Memberships

American College of Physicians - ACP
Member
American Society of Hematology - ASH
Member
American Society of Clinical Oncology - ASCO
Member
American Society for Transplantation and Cellular Therapy - ASTCT
Member
Blood & Marrow Transplant Clinical Trials Network - BMT CTN
Member

Other Languages

Hindi, Urdu, Punjabi

External Links

LinkedInhttps://www.linkedin.com/in/mumushtaq/
Google Scholarhttps://scholar.google.com/citations?hl=en&user=CzpYfMYAAAAJ
My Bibliography (NIH)https://www.ncbi.nlm.nih.gov/myncbi/1TKnUcnWu6tQn-/bibliography/public/

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Similar Physicians & HCPs

Joseph McGuirk, DO
OncKansas City, KS
Christopher Sirridge, MD
OncKansas City, KS
Jeffrey Weitzel, MD
OncKansas City, KS
Allan Fleming, MD
OncKansas City, KS
Marc Hoffmann, MD
OncKansas City, KS
Srikant Nannapaneni, MD
OncKansas City, KS
Kenneth Byrd, DO
OncKansas City, KS
Kyle Work, DO
OncKansas City, KS
Konstantine Halkidis, MD
OncKansas City, KS
Tolga Tuncer, MD
OncKansas City, KS

Doximity / States / Kansas / Kansas City / Muhammad Umair Mushtaq, MD

Dr. Muhammad Umair Mushtaq, Dr. Muhammad Umair Mushtaq, MD, Dr. M Mushtaq